TL;DR
Prime for Young Adults — start your free trial
Fast free delivery, streaming and member deals for eligible 18–24 year olds.
Try it freeAs an affiliate, we earn on qualifying purchases.
ADMA Biologics has announced that August 10, 2026, is the deadline to apply for a class action lawsuit. The company’s legal situation is under review, and investors should be aware of the upcoming deadline.
ADMA Biologics, Inc. has announced that August 10, 2026 is the deadline for filing applications for a class action lawsuit against the company. The legal action is linked to ongoing disputes involving shareholders and corporate conduct, with law firm Kahn Swick & Foti, LLC facilitating the process. This development is significant for investors and stakeholders monitoring the company’s legal and financial status.
ADMA Biologics, Inc., a biopharmaceutical company specializing in plasma-derived therapies, has publicly disclosed the deadline for class action lawsuit applications as August 10, 2026. The announcement was made through a press release on PR Newswire, indicating the company’s acknowledgment of ongoing legal proceedings involving shareholders.
The law firm Kahn Swick & Foti, LLC is representing plaintiffs in this case, and interested parties are advised to contact attorney Lewis Kahn for further guidance before the deadline. The lawsuit reportedly relates to alleged misconduct or misrepresentations by ADMA Biologics, though specific claims have not been publicly detailed.
It is not yet clear what specific allegations are involved or how the legal case might impact the company’s operations or stock performance. The company has not issued additional statements about the lawsuit beyond the deadline announcement.
Legal Implications for ADMA Biologics Investors
This announcement is important because it signals ongoing legal challenges that could influence ADMA Biologics’ financial health and stock value. Shareholders and potential investors should monitor developments, as a successful class action could result in financial liabilities or reputational damage for the company.
The deadline also emphasizes the importance of legal recourse for shareholders who believe they have been misled or harmed by the company’s conduct, potentially affecting future corporate governance and transparency.
As an affiliate, we earn on qualifying purchases.
Background on ADMA Biologics and Legal Proceedings
ADMA Biologics, Inc. has been operating in the plasma-derived therapies sector, with a focus on immune globulin products. The company has faced various challenges, including regulatory scrutiny and market competition.
In recent months, there have been reports of shareholder dissatisfaction and legal actions related to corporate disclosures or management decisions. The announcement of the class action lawsuit deadline indicates that legal proceedings are advancing, though specific details remain undisclosed.
Historically, class actions against biotech firms often involve allegations of misleading statements, failure to disclose material information, or shareholder losses tied to company performance or regulatory issues.
“Interested parties should contact us before the August 10, 2026 deadline to participate in the class action.”
— Lewis Kahn, Esq., Kahn Swick & Foti, LLC
As an affiliate, we earn on qualifying purchases.
Details of the Lawsuit Claims Still Unclear
It is not yet confirmed what specific allegations are being made against ADMA Biologics or how the case might unfold. The company has not provided detailed information about the grounds for the lawsuit or potential damages.
Further disclosures from the plaintiffs or legal filings are needed to clarify the scope and impact of the legal action.
As an affiliate, we earn on qualifying purchases.
Potential claimants should contact Kahn Swick & Foti, LLC before the August 10, 2026 deadline to participate in the class action. Investors and analysts will also need to monitor ADMA Biologics’ official statements and legal filings for updates on the case’s progress.
Legal proceedings may extend beyond the deadline, and further developments could influence the company’s stock price and reputation. The company may also issue additional disclosures or updates as the case advances.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the reason for the class action lawsuit against ADMA Biologics?
The specific allegations have not been publicly disclosed. The lawsuit reportedly involves shareholder claims related to corporate conduct or disclosures, but details are still emerging.
Who can participate in the lawsuit?
Shareholders or investors who believe they have been harmed by ADMA Biologics’ actions can contact the law firm Kahn Swick & Foti, LLC, before the August 10, 2026 deadline to participate.
Will this legal action affect ADMA Biologics’ stock price?
The potential impact on stock price depends on the case’s outcome and the allegations’ nature. Investors should follow official updates for more clarity.
Has ADMA Biologics responded to the lawsuit?
The company has issued no public statements beyond announcing the deadline for lawsuit applications.
What happens after the August 10, 2026 deadline?
Legal proceedings will continue, and further updates from the plaintiffs and the company are expected. Stakeholders should stay informed through official channels.
Source: primary
NFL season / tailgating Picks
team gear
As an affiliate, we earn on qualifying purchases.
